BioTuesdays
ViewRay Logo

BTIG cuts ViewRay PT to $6 from $10

BTIG lowered its price target for ViewRay (NASDAQ:VRAY) to $6 from $10 after the company reported second quarter results. The stock closed at $6.74 on Aug. 8 but was down to $3.35 in after hours trading. ViewRay, which...

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

BTIG starts Cellectis at buy; PT $37

BTIG launched coverage of Cellectis SA (NASDAQ:CLLS; Euronext Growth:ALCLS) with a “buy” rating and $37 price target. The stock closed at $13.86 on Aug. 8. “Despite the initial positive reaction from investors to...

Organovo Holdings

HCW cuts Organovo to neutral and removes PT

H.C. Wainwright downgraded Organovo Holdings (NASDAQ:ONVO) to “neutral” from “buy” and removed its price target after the company engaged a financial advisor to assist management in exploring strategic alternatives. The...

Inogen

Stifel cuts Inogen to hold; PT to $48 from $85

Stifel downgraded Inogen (NASDAQ:INGN) to “hold” from “buy” and lowered its price target to $48 from $85 after the company’s second quarter sales missed consensus estimates and it reduced 2019 guidance. The stock closed...

TransEnterix Logo

BTIG halves TransEnterix PT to $1.50 from $3

BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

H.C. Wainwright downgraded Rexahn Pharmaceuticals (NASDAQ:REXN) to “neutral” from “buy” and slashed its price target to $3 from $23 after a disappointing update from the company’s Phase 2a pancreatic cancer study...

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

AxoGen

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

BTIG ups Tactile Systems to buy with $62 PT

BTIG upgraded Tactile Systems Technology (NASDAQ:TCMD) to “buy” from “neutral” with a price target of $62. The stock closed at $49.30 on Aug. 6. Tactile Medical is a leader in developing and marketing at-home therapy...